Human Monoclonal Antibody Articles & Analysis: Older
7 articles found
In this blog, we will explore the groundbreaking preclinical work on CSX-1004, a fully human monoclonal antibody with exceptional affinity for fentanyl and associated analogs, offering hope in the battle against opioid overdose ...
For example, Biocytogen’s Trop-2/PTK7 dual-antibody ADC BCG033, Trop-2/EGFR dual-antibody ADC DM001, and Trop-2/HER2 dual-antibody ADC YH012, etc. ...
Antibodies are the precise guidance components of ADCs. In theory, molecules that bring effector molecules to the surface of tumor cells can play the role of antibody guidance The choice of antibody for ADC drugs depends on the target of the disease. ...
On February 24, 2023, The NMPA approved Enhertu, an injectable drug developed jointly by AstraZeneca and Daiichi Sankyo, for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have previously received one or more anti-HER2 drugs. Dertrastuzumab is an antibody-drug conjugate (ADC) drug consisting of a humanized ...
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). ...
STEAP1 is an ion/protein transporter and an ideal target for ADCs because it is highly expressed in PCa cells but very low in normal tissues. DSTP3086S, a humanized IgG1 anti-steap1 monoclonal antibody related to MMAE, demonstrated safety and significant antitumor activity in a Phase I trial of 77 mCRPC patients. ...
In 1958, Mathe first conjugated anti-mouse antibody with methotrexate for the treatment of leukemia. Because of the problems of immunogenicity and antibody preparation, ADC drugs stopped decades ago, until the emergence of monoclonal antibodies in 1975, and later the emergence of humanized ...